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Cell Surface Antigens of Mycoplasma Species Bovine Group 7
Bind to and Activate Plasminogen.
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Mycoplasma species bovine group 7 bound plasminogen at the cell surface in a lysine-dependent manner.
Cell-bound plasminogen was rapidly activated to plasmin by exogenous urokinase, and this activity was
associated with plasminogen binding capacity. Binding assays using plasminogen modified with a trifunctional
cross-linking agent revealed several binding proteins.
A small cell size and the total lack of a cell wall are pheno-
typic properties that distinguish mycoplasmas from other bac-
terial species. Many mycoplasmas lack genes involved in bio-
synthetic pathways (e.g., tricarboxylic acid cycle, oxidative
phosphorylation, amino acid, and lipid synthesis pathways),
which is reflected by their comparatively small genome sizes
(28). Mycoplasmas are parasites of a wide variety of eukaryotes
and prefer to scavenge macromolecules and essential nutrients
from their host. Mycoplasmas exhibit a strict host range, typ-
ically displaying organ and tissue specificity, and are usually
found in association with the surfaces of eukaryotic cells, al-
though there is increasing evidence that some species can in-
vade tissues (28, 34, 36).
Mycoplasmas play an important role in infectious diseases
affecting mucosal surfaces, joints, and internal organs of hu-
mans, mammals, reptiles, arthropods, birds, and fish (see ref-
erence 28 and references therein). Several Mycoplasma spe-
cies, including Mycoplasma bovis and Mycoplasma sp. bovine
group 7, have been identified as etiological agents of mastitis
and polyarthritis in cattle (9, 23). Mastitis is a chronic inflam-
matory disease in cattle and is the cause of substantial eco-
nomic losses worldwide (19). Mechanisms of adherence, colo-
nization, and invasion in mycoplasmas are comparatively
poorly understood compared to those in bacterial pathogens
that are more amenable to genetic manipulation. Bovine my-
coplasmal pathogens are transferred between animals by direct
contact, consumption of contaminated milk (mastitic milk),
and/or inhalation of mucus droplets. Thus, these organisms
require a mechanism(s) to travel to and invade the bovine
mammary gland. Mycoplasma sp. bovine group 7 has long been
implicated as a causative agent of polyarthritis and mastitis in
Australian dairy herds (1, 9, 32). Recently, Mycoplasma sp.
bovine group 7 was implicated as the cause of polyarthritis,
mastitis, and abortion in a large, centrally managed dairy in
southwest Sydney, Australia (9). Genetic fingerprinting studies
of 24 epidemiologically related strains recovered from multiple
tissue sites and body fluids of infected calves with polyarthritis,
from mastitic milk, and from the stomach contents, lungs, and
livers of aborted fetuses showed a clonal pattern (6). However,
this clonal pattern was clearly distinguishable from the finger-
print patterns representative of group 7 strains recovered from
unrelated outbreaks and sporadic episodes both within Aus-
tralia and overseas (6). These data suggest that bovine group 7
can be a virulent, invasive organism able to cause systemic
infection.
Plasminogen, a 92-kDa plasma glycoprotein, is activated to
the proteolytic enzyme plasmin by eukaryotic and prokaryotic
secreted activators (5, 24). Plasmin has a number of tightly
regulated physiological functions, including the degradation of
fibrin clots and extracellular matrix proteins during cell migra-
tion (17, 24). Plasminogen binds to exposed lysine residues on
cell surfaces or in fibrin structures via lysine binding sites
within the N-terminal binding domain of the molecule (4, 25).
The C-terminal protease domain contains a classic serine pro-
tease triad (4, 25).
A number of bacterial pathogens are known to acquire host
plasminogen on their cell surface to assist in the invasion and
colonization of bovine mammary tissue (5, 16, 24). Despite the
recognized importance attributed to mycoplasmal infections
affecting cattle, the mechanisms used by mycoplasmas for tis-
sue colonization and invasion remain elusive. Recently, studies
by Yavlovich et al. (36) described the binding and activation of
human plasminogen on the surface of Mycoplasma fermentans
by a urokinase-type plasminogen activator (uPA). These
events were shown to promote the invasion of HeLa cells by
M. fermentans. The aims of our study were to (i) determine if
Mycoplasma sp. bovine group 7 is capable of binding to and
activating plasminogen and (ii) detect plasminogen binding
proteins by using various ligand blotting procedures.
Bacterial strains and media. Mycoplasma species bovine
group 7 type strain PG50 (isolate 23) and field isolate 4 were
obtained from a collection of group 7 mycoplasmas housed at
the Elizabeth Macarthur Agricultural Institute, Camden, New
South Wales, Australia, and their isolation has been described
previously (9). M. bovis type strain NCTC 10131 (PG45) (a gift
from R. Hirst) and field strain 20 (kindly supplied by J. Forbes-
Faulkener) were also examined for their ability to bind plas-
minogen. Each of these strains was grown in a modified Friis
broth or on Friis agar as described by Hum et al. (9). The
mycoplasma cells were pelleted by centrifugation at 8,000  g
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for 30 min in culture, followed by centrifugation at 11,000  g
for 30 min in phosphate-buffered saline (PBS) (pH 7.4). The
number of viable cells was determined as CFU.
Human and bovine plasminogen sequence comparison. Hu-
man and bovine glu-plasminogen (accession numbers P00747
and P06868, respectively) were shown to be 78% identical
(82% conserved) at the amino acid level overall and were
considered equivalent for experimental purposes (31).
Plasminogen isolation and modification. Bovine and human
glu-plasminogen were isolated from plasma by using lysine-
Sepharose chromatography as described by Andronicos et al.
(2). Both human and bovine glu-plasminogen were conjugated
with fluorescein isothiocyanate (FITC) (isomer 1) (Sigma
Chemical Co.) as described previously (7), and the differences
in ratios of FITC conjugation to human and bovine plasmin-
ogen (factor of 2.45) were normalized after measuring the
fluorescence of each preparation with a Biolumin 960 fluorim-
eter (Molecular Dynamics). Modification of plasminogen in
this manner or with NHS-biotin (Pierce) has been shown to
retain the lysine binding activity of the molecule (2, 27).
Human glu-plasminogen was conjugated to the trifunctional
cross-linking agent sulfosuccinimidyl-2-[6-(biotinamido)-2-(p-
azidobenzamido)-hexanoamido]-ethyl-1,3-dithiopropionate
(sulfo-SBED) (Pierce) according to the manufacturer’s in-
structions. Plasminogen modified with this agent (referred to
as S-plasminogen) retains its lysine binding capacity as as-
sessed by lysine-Sepharose chromatography (data not shown).
FITC-plasminogen binding assay. To perform binding and
activation assays, mycoplasma cells were fixed in 1% parafor-
maldehyde dissolved in PBS at a stock concentration equiva-
lent to 1013 cells/ml. For binding assays, a fixed stock solution
of cells was pelleted by centrifugation at 14,000  g for 15 min,
washed three times with chilled PBSB (PBS containing 0.1%
[wt/vol] bovine serum albumin), and resuspended in PBSB at a
final concentration of 5  1012 cells/ml. The cells were then
incubated with 100 g of FITC-labeled plasminogen per ml in
the absence or presence of the lysine analogue tranexamic acid
(TA) (1 mM; Sigma Chemical Co.) for 45 min in the dark
on ice. The cells were then washed twice as described above
and finally resuspended in 300 l of PBS for flow cytometry
(FACSort; Becton Dickinson) as described previously (27).
Autofluorescence levels for each mycoplasma strain were mea-
sured and subtracted from each assay result. All data were
analyzed with CellQuest software (Becton Dickinson). Control
experiments confirmed a direct correlation between the capac-
ity to bind plasminogen and mycoplasma cell number (data not
shown). Furthermore, binding of plasminogen to mycoplasma
cells was concentration dependent (data not shown).
Plasminogen activation assay. The generation of cell surface
plasmin by uPA was detected by spectrophotometric deter-
mination with the chromogenic plasmin substrate Spectro-
zyme-PL (American Diagnostica Inc.). The optimal concentra-
tion of uPA was determined by construction of a kinetic
concentration curve of plasmin activity resulting from the in-
cubation of various concentrations of human uPA (Calbio-
chem) with plasminogen (100 g/ml) and Spectrozyme-PL
(250 mol/liter). Fixed stock solutions of mycoplasmas were
washed three times with cold PBSB, resuspended in PBSB at a
final concentration of 5  1012 cells/ml, and incubated with
various concentrations of plasminogen (0 to 100 g/ml). The
cells were then washed and resuspended in Tris-buffered saline
(TBS) and incubated at 37°C with 30 IU of uPA per ml and 250
mol of Spectrozyme-PL per liter in a final reaction volume of
100 l. Color development was monitored at 415 nm over 45
min with a 96-well Spectra Max 250 microplate reader (Mo-
lecular Devices). The plasmin activity generated on the cell
surface was extrapolated from a plasmin (American Diagnos-
tica Inc.) standard curve.
Plasminogen ligand blotting analysis. Plasminogen ligand
blotting analyses were conducted as previously described (2)
with minor modifications. Whole mycoplasma cell lysates were
prepared in nonreducing sample buffer, and the proteins were
fractionated on sodium dodecyl sulfate (SDS)–10% polyacryl-
amide gels and transferred to polyvinylidene difluoride (PVDF)
membranes. The membranes were washed once with TNCM (50
mM Tris-HCl [pH 7.5], 150 mM NaCl, 2 mM CaCl2, 3 mM
MgCl2) and blocked with TNCM–2% polyvinyl pyrrolidine 40
(TNCM–PVP-40) overnight at room temperature. The mem-
branes were then probed with 5 nM biotinylated glu-plasmin-
ogen in the absence or presence of 100 mM ε-amino caproic
acid in TNCM–PVP-40 containing 0.05% (vol/vol) Tween 20
(TNCMT) for 45 min and washed for 1 h with three changes of
TNCMT. Membranes were probed with a 1:4,000 dilution of
horseradish peroxidase (HRP)-conjugated neutravidin (Cal-
biochem) in TNCMT–PVP-40 for 1 h, followed by three
washes with TNCMT and one wash with TNCM. The blots
were then developed by enhanced chemiluminescence (Super-
Signal; Pierce).
Cell surface sulfo-SBED–plasminogen binding analysis. A
novel approach was developed for the detection of cell surface
plasminogen binding proteins by using S-plasminogen. Sulfo-
SBED is built on a biocytin backbone and contains two chem-
ically reactive groups, a sulfo-NHS arm for ligand coupling
with a cleavable disulfide bridge and a photosensitive phenyl
azide that is activated by long-wave UV light (8). Since the
sulfo-NHS arm and phenyl azide arm are only 22.8 Å apart,
S-plasminogen can be cross-linked to cell surface receptor pro-
teins via the phenyl azide group (8). Lysis of the cells in a buffer
containing a disulfide reducing agent allows biotin label trans-
fer to the plasminogen receptor(s). Similar methods have been
used successfully to detect cell surface receptors. For example,
Rabin et al. (26) modified lipopolysaccharide with a radiola-
beled sulfo-NHS-based photoactive cross-linker to identify its
major binding site on human monocytes.
The S-plasminogen binding assay was performed with live
mycoplasma cells under the same conditions as the FITC-
plasminogen binding assays with the following modifications.
First, to maintain cell viability (90%), mycoplasma cells were
centrifuged at 11,000  g. Cell viability was monitored by
propidium iodide (Sigma Chemical Co.) staining of samples
and measurement with a Biolumin 960 fluorimeter; loss of
viability corresponds to increased fluorescence due to nuclear
staining (27). Following incubation, unbound S-plasminogen
was removed by washing with PBS, and the cells were exposed
to long-wavelength UV light (365 nm) for 20 min at a distance
of 5 cm on ice by using the UV Stratalinker 1800 (Stratagene).
These conditions gave maximal cross-linking activity (data not
shown). The cells were then pelleted as described above and
resuspended in reducing SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) buffer at an approximate final concen-
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tration of 2.5  1014 cells/ml. The whole-cell lysates were
separated by SDS–12% PAGE, and proteins were transferred
to PVDF membranes. For detection of biotin-labeled proteins,
the membranes were washed in TBST (50 mM Tris-HCl [pH
8.0], 150 mM NaCl, 0.05% [vol/vol] Tween 20), blocked in
TBST–10% milk powder at room temperature for 1 to 2 h,
rinsed in TBST, and incubated with a 1:8,000 dilution of horse-
radish peroxidase-conjugated neutravidin dissolved in 2%
milk–TBST for 1 h at room temperature. After three washes
with TBST and one wash with TBS, the complexes were de-
tected by enhanced chemiluminescence.
The ability of human and bovine plasminogen to bind in a
lysine-dependent manner to cell surfaces of paraformalde-
hyde-fixed mycoplasmal strains was assessed semiquantita-
tively by flow cytometry (Fig. 1). A comparison of normalized
human and bovine FITC-plasminogen lysine-dependent bind-
ing to two strains of Mycoplasma sp. bovine group 7 was made
under optimal conditions (Fig. 1B). For both human and bo-
vine plasminogen, the binding capacity was fourfold higher in
strain PG50 than in strain 4 (P  0.01). While there was no
significant difference between human and bovine plasminogen
binding to PG50, there was a significant difference with strain
4 (0.01  P  0.05). Control experiments using two strains of
M. bovis (PG45 and field strain 20) also showed no significant
difference between human and bovine plasminogen binding
capacities, both of which were similar to that of strain 4 (Fig.
1B). This result suggests that in most cases there is no species
difference in the utilization of plasminogen. McCoy et al. (18),
who studied human, equine, and porcine plasminogen binding
to human equine and porcine strains of streptococci, also
found that there was no species preference for the host plas-
minogen.
Activation of bound plasminogen by uPA was concentration
dependent for both strains of Mycoplasma sp. bovine group 7
(data not shown). At 100 g of plasminogen per ml, PG50
generated approximately 10-fold more plasmin than strain 4
(Fig. 2), reflecting its high human/bovine plasminogen binding
capacity (Fig. 1). We were unable to show any plasmin activity
on cells in the absence of added plasminogen or uPA. This
observation indicates that these mycoplasmas do not produce
their own plasminogen activators. Yavlovich et al. (36) also
found that plasminogen bound to M. fermentans could not be
activated in the absence of added activators. The level of plas-
minogen activation on the cell surface of both strains under
these conditions may not reflect their activation potential in
vivo, as other activators such as tissue type plasminogen acti-
vator (33) may more efficiently activate plasminogen on these
strains.
Since maximal plasminogen binding and activation occurred
with the group 7 type strain PG50, the following experiments
focused on this strain. Ligand blots of whole-cell lysates of
PG50 with biotinylated plasminogen showed the presence of
five easily distinguishable lysine-dependent binding proteins
ranging in molecular mass from 14 to 55 kDa (Fig. 3). Over-
exposed blots showed the presence of two other weakly binding
plasminogen receptor proteins with approximate molecular
masses of 18 and 40 kDa (data not shown). The presence of
multiple plasminogen binding proteins in other Mycoplasma
strains (36) and various other prokaryotes (3, 15, 22, 30, 35)
has been reported previously.
Ligand blots of whole-cell lysates do not definitively distin-
guish bona fide cell surface plasminogen binding proteins from
proteins that reside intracellularly and fortuitously bind plas-
minogen (27). A second assay was developed to identify cell
surface plasminogen binding proteins by using S-plasminogen.
By this method, it is clear that there are multiple (at least six)
plasminogen binding proteins of relatively equal abundances
on the cell surface of strain PG50, ranging in size from approx-
imately 20 to 55 kDa (Fig. 4, lane 2). Lower blot exposure
times (data not shown) confirmed the presence of two distin-
guishable plasminogen binding proteins at approximately 45
kDa. Furthermore, a weak plasminogen binding protein band
FIG. 1. Cell surface FITC-plasminogen binding to mycoplasma
strains. (A) Representative histogram plot of FITC-labeled human
plasminogen binding to strain PG50, showing relative FITC fluores-
cence intensity (FLH-1) verses cell count. Autofluorescence relates to
background levels of cellular fluorescence measured in the absence
of FITC-plasminogen. The amount of lysine-dependent binding was
measured as the difference between the geometric means of FITC-
plasminogen (plg) and FITC-plasminogen plus TA (plgTA). (B)
Comparison of human (open bars) and bovine (filled bars) lysine-de-
pendent FITC-plasminogen binding to four mycoplasmal strains. The
concentrations of human FITC-plasminogen (50 g/ml), TA (1 mM),
and cells (5  1012 cells/ml) remained constant for each assay. Bars
indicate means  standard errors of the means (n  3). **, statistically
significant difference between strain PG50 and strain 4 for both human
and bovine plasminogen binding (P  0.05). *, significant difference
between human and bovine plasminogen binding in strain 4 only (P 
0.01).
VOL. 71, 2003 NOTES 4825



















with an approximate molecular mass of 50 kDa was also evi-
dent (Fig. 4, lane 2). Control assays performed in the absence
of S-plasminogen (Fig. 4, lane 1), or in the presence of S-
plasminogen and TA (Fig. 4, lane 3) indicated that there were
no detectable naturally biotinylated proteins present in the
whole-cell lysate of strain PG50 and that none of the S-plas-
minogen binding occurred in a non-lysine-dependent manner,
as biotin had not been transferred to any of the proteins. It was
possible that trace levels of S-plasminogen (92 kDa) or light
(25 kDa) and heavy chains (65 kDa) of S-plasmin in the prep-
aration contributed to the biotinylated proteins detected in
Fig. 4. To investigate this, the blots were also probed with a
rabbit antiplasminogen polyclonal antibody followed by a goat
anti-rabbit–HRP polyclonal antibody (data not shown). Pro-
teins with apparent molecular masses of 185, 92, and 66 kDa
were detected, corresponding to S-plasminogen dimer, S-plas-
minogen monomer, and S-plasmin heavy chain, respectively
(data not shown). These results indicate that all other bands
shown in Fig. 4 are likely to represent plasminogen binding
proteins of mycoplasmal origin.
Many studies conducted on streptococcal pathogens have
shown that there are variations in plasminogen binding capac-
ity between species and strains of species (10, 11, 12, 13, 18). A
direct comparison between plasminogen binding to the four
different strains of mycoplasmas further supported this obser-
vation, as the different species displayed variations in plasmin-
ogen binding capacity.
Numerous diverse plasminogen receptors on mammalian
cells (14, 20, 27, 29) and bacterial pathogens (3, 15, 21, 22, 30,
35), including mycoplasmas (36), have been reported. Yavlov-
ich et al. (36), using an 125I-labeled plasminogen ligand blot
and autoradiography detection system with M. fermentans
plasma membranes, detected two putative plasminogen recep-
tors of approximately 32 and 55 kDa. We detected several
potential receptors in Mycoplasma sp. bovine group 7 by using
either ligand blots of whole-cell extracts or the novel S-plas-
minogen label-transfer assay with intact live cells, which was
designed to ensure the detection of cell surface binding moi-
eties. While the proteins detected by both methods fall into the
same molecular mass range (i.e., 	15 to 55 kDa), at this stage
it is not possible to say whether the repertoires of proteins
detected by either method are identical. Future experiments
will be aimed at identifying these proteins and confirming them
as bona fide plasminogen receptors not only by determining
the ability of recombinant proteins to bind to and activate
FIG. 2. Cell surface plasmin activity. Fixed mycoplasma strains
PG50 and 4 were incubated with 100 g of human glu-plasminogen per
ml. Plasminogen activation by uPA (30 IU) was then determined by
incubation with the Spectrozyme-PL plasmin substrate for 30 min.
Bars indicate means  standard errors of the means (n  3). *, sta-
tistically significant difference between strain PG50 and strain 4 (P 
0.05).
FIG. 3. Biotinylated plasminogen ligand blot with whole-cell ly-
sates of strain PG50. Whole-cell lysates were fractionated by SDS–12%
PAGE (approximately 30 g/lane), and the proteins were transferred
to PVDF and subjected to ligand blotting with 5 nM biotinylated
human glu-plasminogen (lanes 2) in the presence (A) or absence (B)
of 100 mM ε-amino caproic acid. Lanes 1, biotinylated low-molecular-
mass markers (Bio-Rad). After ligand analysis, the blots were washed
and briefly stained with amido black to show the amount of protein
transferred (lanes 3). All blots shown were derived from gels run,
transferred, and probed in parallel and were exposed onto the same
piece of autoradiograph film so that a direct comparison could be
made between them. Note the absence of lysine-dependent plasmino-
gen binding proteins in panel A (lane 2). Molecular masses of pre-
stained molecular mass markers are as indicated.
FIG. 4. Protein blot analysis of mycoplasma cell surface S-plasmin-
ogen binding proteins from strain PG50. Cells were incubated either in
the absence of S-plasminogen (lane 1), in the presence of S-plasmin-
ogen alone (lane 2), or in the presence of S-plasminogen and 1 mM TA
(lane 3) prior to UV exposure. After UV exposure (which is required
to transfer biotin to plasminogen binding proteins), whole-cell lysates
were prepared and fractionated by reducing SDS–12% PAGE (ap-
proximately 15 g/lane), and the proteins were transferred to PVDF
membranes. The blot shows biotin-labeled lysine-dependent plasmin-
ogen binding proteins (thin arrows) detected with neutravidin-HRP
followed by chemiluminescence. Thick arrows indicate traces of S-plas-
minogen detected with neutravidin-HRP. Molecular masses of molec-
ular mass markers are as indicated.
4826 NOTES INFECT. IMMUN.



















plasminogen but also by providing evidence of cell surface
localization. Nevertheless, it is clear that a number of different
plasminogen binding proteins were detected on the group 7
type strain PG50 cell surface, suggesting that there is no one
protein responsible for localizing plasminogen on these myco-
plasmas.
This is the first study to report plasminogen binding and
activation at the cell surface of bovine mycoplasmas associated
with mastitis. Currently, the molecular basis by which myco-
plasmal mastitis pathogens invade and stably infect the host
bovine mammary gland remains largely elusive. A number of
other nonmycoplasmal mastitis pathogens are known to be-
come pathogenic by using the host plasminogen system (5, 10,
12). It is therefore plausible that plasminogen binding and
activation are a virulence determinant of mycoplasmas and
provides a means of invading the mammary gland, resulting in
bovine mastitis pathology.
We are grateful for the excellent technical assistance of Wendy
Forbes. We thank Robert Hirst and Judy Forbes-Faulkner for kindly
supplying M. bovis type strain PG45 and field strain 20, respectively.
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